Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000583274 | SCV000689604 | likely benign | Hereditary cancer-predisposing syndrome | 2017-09-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001442310 | SCV001645259 | likely benign | Familial melanoma | 2024-10-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000583274 | SCV002623549 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-01-26 | criteria provided, single submitter | clinical testing | The c.388C>T variant (also known as p.L130L), located in coding exon 2 of the CDKN2A gene, results from a C to T substitution at nucleotide position 388. This nucleotide substitution does not change the leucine at codon 130. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive; and direct evidence is insufficient at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |